{"id":50092,"date":"2025-12-08T19:19:04","date_gmt":"2025-12-08T18:19:04","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2025\/12\/08\/a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor\/"},"modified":"2025-12-08T19:19:04","modified_gmt":"2025-12-08T18:19:04","slug":"a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2025\/12\/08\/a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor\/","title":{"rendered":"A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor"},"content":{"rendered":"<div>\n<p><b>Cancer Immunol Res<\/b>. 2025 Dec 8. doi: 10.1158\/2326-6066.CIR-25-0070. Online ahead of print.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Vaccines that encode tumour-associated antigens are potent boosting agents for adoptively transferred tumour-specific T cells. Employing vaccines to boost adoptively transferred tumour-reactive T cells relies on a priori knowledge of tumour epitopes, isolation of matched epitope-specific T cells, and personalized vaccines, all of which limit clinical feasibility. Here, we investigated a universal strategy for boosting transferred tumour-specific T cells where boosting is provided through a chimeric antigen receptor (CAR) that is paired with a vaccine encoding the CAR target antigen. To this end, we developed and employed a model wherein murine T cells expressing a TCR specific for antigen on syngeneic tumours were engineered with boosting CARs against a distinct surrogate boosting antigen for studies in immunocompetent hosts. Boosting CAR-engineered tumour-specific T cells with paired vesicular stomatitis virus (VSV) vaccines was associated with robust T cell expansion and delayed tumour progression in the absence of prior lymphodepletion. CAR-T cell expansion and antitumour function was further enhanced by blocking IFNAR1. However, vaccine-boosted CAR-T cells rapidly contracted and antigen-positive tumours re-emerged. In contrast, when the same T cells were boosted with a vaccine encoding antigen that stimulates through the TCR, the adoptively transferred T cells displayed improved persistence, tumour-specific endogenous cells expanded in parallel, and tumour cells carrying the antigen target were completely eradicated. Our findings underscore the need for further research into CAR-mediated vaccine boosting, how this differs mechanistically from TCR-mediated boosting, and the importance of engaging endogenous tumour-reactive T cells during vaccination to achieve long-term tumour control.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41359369\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=101614637&amp;ff=20251208131903&amp;v=2.18.0.post22+67771e2\">41359369<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0070\">10.1158\/2326-6066.CIR-25-0070<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Cancer Immunol Res. 2025 Dec 8. doi: 10.1158\/2326-6066.CIR-25-0070. Online ahead of print. ABSTRACT Vaccines that encode tumour-associated antigens are potent boosting agents for adoptively transferred tumour-specific T cells. Employing vaccines to boost adoptively transferred tumour-reactive T cells relies on a priori knowledge of tumour epitopes, isolation of matched epitope-specific T cells, and personalized vaccines, all &#8230; <a title=\"A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2025\/12\/08\/a-universal-boosting-strategy-for-adoptive-t-cell-therapy-using-a-paired-vaccine-chimeric-antigen-receptor\/\" aria-label=\"Read more about A universal boosting strategy for adoptive T cell therapy using a paired vaccine\/chimeric antigen receptor\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[55,42],"tags":[],"class_list":["post-50092","post","type-post","status-publish","format-standard","hentry","category-cancer-immunology-reserch","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/50092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=50092"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/50092\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=50092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=50092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=50092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}